Patents by Inventor Norbert Waldöfner

Norbert Waldöfner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9962442
    Abstract: The present invention relates to a method for producing a suspension of agglomerates of magnetic alkoxysilane-coated metal nanoparticles, wherein an aqueous suspension of magnetic metal nanoparticles is incubated with alkoxysilane, wherein the incubation is carried out essentially in the absence of an organic solvent. The present invention further relates to suspension of agglomerates of magnetic alkoxysilane-coated metal containing nanoparticles obtainable by the method of the present invention and to a composition comprising agglomerates of magnetic alkoxysilane-coated metal nanoparticles, wherein the agglomerates have an average size of 30 to 450 nm, preferably of 50 to 350 nm and especially of 70 to 300 nm as determined by light scattering.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: May 8, 2018
    Assignee: MAGFORCE AG
    Inventors: Norbert Waldoefner, Andreas Jordan
  • Patent number: 9827312
    Abstract: The present invention relates to compositions containing nanoparticies and uses of said composition for transferring therapeutically active substances into cells by means of specifically coated nanoparticles. The chemical design of the particles is such that a large amount thereof is absorbed into the cells. No direct bond between nanoparticle and the therapeutically active substance is required for the transfer into the cells. Thanks to said transfer, an increased efficacy of the substance and simultaneously reduced systemic toxicity is achieved, i.e. an increase in the efficacy while the side effects are reduced.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: November 28, 2017
    Assignee: MAGFORCE AG
    Inventors: Andreas Jordan, Norbert Waldoefner, Regina Scholz
  • Patent number: 9814677
    Abstract: Embodiments herein relate to the production of biocompatible magnetic nanoparticles with a high SAR-value which produce a large amount of heat when exposed to an alternating magnetic field. The produced heat can be used among others for therapeutic purposes, in particular for combating cancer.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: November 14, 2017
    Assignee: MAGFORCE AG
    Inventors: Norbert Waldoefner, Kerstin Stief
  • Publication number: 20160367673
    Abstract: The present invention relates to a method for producing a suspension of agglomerates of magnetic alkoxysilane-coated metal nanoparticles, wherein an aqueous suspension of magnetic metal nanoparticles is incubated with alkoxysilane, wherein the incubation is carried out essentially in the absence of an organic solvent. The present invention further relates to suspension of agglomerates of magnetic alkoxysilane-coated metal containing nanoparticles obtainable by the method of the present invention and to a composition comprising agglomerates of magnetic alkoxysilane-coated metal nanoparticles, wherein the agglomerates have an average size of 30 to 450 nm, preferably of 50 to 350 nm and especially of 70 to 300 nm as determined by light scattering.
    Type: Application
    Filed: June 30, 2016
    Publication date: December 22, 2016
    Inventors: Norbert WALDOEFNER, Andreas JORDAN
  • Patent number: 9408912
    Abstract: The present invention relates to a method for producing a suspension of agglomerates of magnetic alkoxysilane-coated metal nanoparticles, wherein an aqueous suspension of magnetic metal nanoparticles is incubated with alkoxysilane, wherein the incubation is carried out essentially in the absence of an organic solvent. The present invention further relates to suspension of agglomerates of magnetic alkoxysilane-coated metal containing nanoparticles obtainable by the method of the present invention and to a composition comprising agglomerates of magnetic alkoxysilane-coated metal nanoparticles, wherein the agglomerates have an average size of 30 to 450 nm, preferably of 50 to 350 nm and especially of 70 to 300 nm as determined by light scattering.
    Type: Grant
    Filed: August 7, 2012
    Date of Patent: August 9, 2016
    Assignee: MagForce AG
    Inventors: Norbert Waldöfner, Andreas Jordan
  • Patent number: 9345768
    Abstract: The present invention relates to nanoparticles, wherein at least one therapeutically active substance is bound to said nanoparticle and wherein the separation of the at least one therapeutically active substance from the nanoparticle is caused or initiated by an alternating magnetic filed. Furthermore, the present invention relates to pharmaceutical compositions, in particular to injection solutions containing the nanoparticles as well as to the use thereof for the treatment of cancer.
    Type: Grant
    Filed: April 12, 2006
    Date of Patent: May 24, 2016
    Assignee: MAGFORCE AG
    Inventors: Andreas Jordan, Norbert Waldoefner, Klaus Decken, Regina Scholz
  • Publication number: 20160067338
    Abstract: The present invention relates to compositions containing nanoparticies and uses of said composition for transferring therapeutically active substances into cells by means of specifically coated nanoparticles. The chemical design of the particles is such that a large amount thereof is absorbed into the cells. No direct bond between nanoparticle and the therapeutically active substance is required for the transfer into the cells. Thanks to said transfer, an increased efficacy of the substance and simultaneously reduced systemic toxicity is achieved, i.e. an increase in the efficacy while the side effects are reduced.
    Type: Application
    Filed: September 9, 2015
    Publication date: March 10, 2016
    Inventors: Andreas JORDAN, Norbert WALDOEFNER, Regina SCHOLZ
  • Publication number: 20140302154
    Abstract: Embodiments herein relate to the production of biocompatible magnetic nanoparticles with a high SAR-value which produce a large amount of heat when exposed to an alternating magnetic field. The produced heat can be used among others for therapeutic purposes, in particular for combating cancer.
    Type: Application
    Filed: May 15, 2014
    Publication date: October 9, 2014
    Applicant: MagForce AG
    Inventors: Norbert WALDOEFNER, Kerstin STIEF
  • Patent number: 8771699
    Abstract: Embodiments herein relate to the production of biocompatible magnetic nanoparticles with a high SAR-value which produce a large amount of heat when exposed to an alternating magnetic field. The produced heat can be used among others for therapeutic purposes, in particular for combating cancer.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: July 8, 2014
    Assignee: Magforce AG
    Inventors: Norbert Waldoefner, Kerstin Stief
  • Publication number: 20140154324
    Abstract: The present invention relates to a method for producing a suspension of agglomerates of magnetic alkoxysilane-coated metal nanoparticles, wherein an aqueous suspension of magnetic metal nanoparticles is incubated with alkoxysilane, wherein the incubation is carried out essentially in the absence of an organic solvent. The present invention further relates to suspension of agglomerates of magnetic alkoxysilane-coated metal containing nanoparticles obtainable by the method of the present invention and to a composition comprising agglomerates of magnetic alkoxysilane-coated metal nanoparticles, wherein the agglomerates have an average size of 30 to 450 nm, preferably of 50 to 350 nm and especially of 70 to 300 nm as determined by light scattering.
    Type: Application
    Filed: August 7, 2012
    Publication date: June 5, 2014
    Inventors: Norbert Waldöfner, Andreas Jordan
  • Publication number: 20120225128
    Abstract: The present invention relates to compositions containing nanoparticies and uses of said composition for transferring therapeutically active substances into cells by means of specifically coated nanoparticles. The chemical design of the particles is such that a large amount thereof is absorbed into the cells. No direct bond between nanoparticle and the therapeutically active substance is required for the transfer into the cells. Thanks to said transfer, an increased efficacy of the substance and simultaneously reduced systemic toxicity is achieved, i.e. an increase in the efficacy while the side effects are reduced.
    Type: Application
    Filed: May 11, 2012
    Publication date: September 6, 2012
    Inventors: Andreas JORDAN, Norbert Waldoefner, Regina Scholz
  • Publication number: 20110052609
    Abstract: Embodiments herein relate to the production of biocompatible magnetic nanoparticles with a high SAR-value which produce a large amount of heat when exposed to an alternating magnetic field. The produced heat can be used among others for therapeutic purposes, in particular for combating cancer.
    Type: Application
    Filed: January 9, 2009
    Publication date: March 3, 2011
    Inventors: Norbert Waldoefner, Kerstin Stief
  • Publication number: 20080268061
    Abstract: The present invention relates to nanoparticles, wherein at least one therapeutically active substance is bound to said nanoparticle and wherein the separation of the at least one therapeutically active substance from the nanoparticle is caused or initiated by an alternating magnetic filed. Furthermore, the present invention relates to pharmaceutical compositions, in particular to injection solutions containing the nanoparticles as well as to the use thereof for the treatment of cancer.
    Type: Application
    Filed: April 12, 2006
    Publication date: October 30, 2008
    Inventors: Andreas Jordan, Norbert Waldoefner, Klaus Decken, Regina Scholz
  • Publication number: 20080187595
    Abstract: The present invention relates to compositions containing nanoparticles and uses of said composition for transferring therapeutically active substances into cells by means of specifically coated nanoparticles. The chemical design of the particles is such that a large amount thereof is absorbed into the cells. No direct bond between nanoparticle and the therapeutically active substance is required for the transfer into the cells. Thanks to said transfer, an increased efficacy of the substance and simultaneously reduced systemic toxicity is achieved, i.e. an increase in the efficacy while the side effects are reduced.
    Type: Application
    Filed: August 21, 2006
    Publication date: August 7, 2008
    Inventors: Andreas Jordan, Norbert Waldoefner, Regina Scholz